Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTHENON: AZD4956 as monotherapy and in combination with saruparib in homologous recombination deficient solid tumours
jRCT2031260176Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of AZD4956 and saruparib in solid neoplasms, breast cancer, ovarian cancer and 4 more (3 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events and serious adverse events, Progression-free survival (PFS) and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
AZD4956saruparib
03
Conditions
solid neoplasmsbreast cancerovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2031260176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260176.